随机非劣效性试验:1600毫克与400毫克美沙拉秦片剂治疗轻中度溃疡性结肠炎的比较
这项随机非劣效性试验纳入817例轻中度活动性溃疡性结肠炎患者,比较每日一次两片1600毫克与每日两次四片400毫克美沙拉秦(均3.2克/日)诱导缓解的疗效与安全性。第8周缓解率分别为22.4%和24.6%,绝对差-2.2%(95%CI:-8.1%至3.8%),非劣效性P=.005,1600毫克片剂被判定为非劣效。
要点
- 1600毫克片剂每日一次两片(3.2克/日)在诱导临床和内镜缓解方面非劣效于400毫克片剂每日两次四片。
- 第8周缓解率:1600毫克组22.4% vs 400毫克组24.6%,绝对差-2.2%(95%CI:-8.1%至3.8%)。
- 内镜和组织病理学疾病活动度、白细胞浓度和年龄与临床缓解显著相关。
核心结论
- 使用两片1600毫克片剂每日一次给予3.2克美沙拉秦的诱导治疗,在统计学和临床上非劣效于使用四片400毫克片剂每日两次的方案。
研究设计与样本
- 随机非劣效性试验,纳入817例轻中度活动性溃疡性结肠炎患者(Mayo诊所评分>5),随机接受3.2克口服美沙拉秦,分为两片1600毫克片剂每日一次组或四片400毫克片剂每日两次组,非劣效性界值为10%。
主要发现
- 第8周,1600毫克片剂组和400毫克片剂组的缓解率分别为22.4%和24.6%(绝对差-2.2%,95%CI:-8.1%至3.8%,非劣效性P=.005)。
- 内镜和组织病理学疾病活动度、白细胞浓度和年龄与临床缓解显著相关(P=.022、.042、.014和.023)。
- 第38周,继续接受1600毫克制剂治疗的患者中43.9%(296/675)处于缓解,其中包括接受美沙拉秦减量至1.6克/日的患者中的70.3%(142/202)。
- 严重不良事件总体发生率低。
关键数值与推荐
- 非劣效性界值为10%。
- 第8周临床和内镜缓解率:1600毫克片剂组22.4% vs 400毫克片剂组24.6%,绝对差-2.2%(95%CI:-8.1%至3.8%),非劣效性P=.005。
- 第38周,继续1600毫克制剂治疗的患者中43.9%(296/675)处于缓解,接受减量至1.6克/日的患者中70.3%(142/202)处于缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis (UC). AIM: To compare the efficacy and safety of 1600 mg and 400 mg tablet mesalazine formulations. METHODS: Patients with mild-to-moderate active UC (Mayo Clinic Score >5; N=817) were randomised to 3.2 g of oral mesalazine, administered as two 1600 mg tablets once, or four 400 mg tablets twice daily. We hypothesised that treatment with the 1600 mg tablet was non-inferior (within a 10% margin) to the 400 mg tablet for induction of clinical and endoscopic remission at week 8. Open-label treatment with the 1600 mg tablet continued for 26-30 weeks based on induction response. Predictors of treatment response were also explored. RESULTS: At week 8, remission occurred in 22.4% and 24.6% of patients receiving the 1600 mg and 400 mg tablets, respectively (absolute difference -2.2%, 95% CI: -8.1% to 3.8%, non-inferiority P=.005). Endoscopic and histopathologic disease activity, leucocyte concentration and age were significantly associated with clinical remission (P=.022, .042, .014 and .023, respectively). At week 38, 43.9% (296/675) of patients who continued treatment with the 1600 mg formulation were in remission, including 70.3% (142/202) of patients who received a reduced dose of mesalazine (1.6 g/d). The overall incidence of serious adverse events was low. CONCLUSIONS: Induction therapy with 3.2 mg mesalazine using two 1600 mg tablets once-daily was statistically and clinically non-inferior to a twice-daily regimen using four 400 mg tablets (NCT01903252).
引用
- D'Haens GR, Sandborn WJ, Zou G, et al. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017. PMID: 28568974. doi:10.1111/apt.14164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。